Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013;8:21–47.

Article  CAS  PubMed  Google Scholar 

SEER*Explorer Application. https://seer.cancer.gov/statistics-network/explorer/application.html?site=409&data_type=1&graph_type=2&compareBy=age_range&chk_age_range_1=1&rate_type=2&sex=1&race=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2. Accessed 1 Aug 2025.

GenoMed4All consortium. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematol. 2023;10:e117–e128.

Feurstein S, et al. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022;140:2533–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochman MJ, DeZern AE. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Lancet Haematol. 2022;9:e523–34.

Article  CAS  PubMed  Google Scholar 

Negoro E, et al. Origins of myelodysplastic syndromes after aplastic anemia. Blood. 2017;130:1953–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Venugopal S, DeZern AE. Therapy-related myelodysplastic syndromes and acute myeloid leukemia. Semin Hematol. 2024;61:379–84.

Article  PubMed  Google Scholar 

Peffault de Latour R, Soulier J. How I treat MDS and AML in Fanconi anemia. Blood. 127:2971–2979.

Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009;113:6549–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calvo KR, Hickstein DD. The spectrum of GATA2 deficiency syndrome. Blood. 2023;141:1524–32.

Article  CAS  PubMed  Google Scholar 

Sahoo SS, Erlacher M, Wlodarski MW. Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management. Blood. 2025;145:475–85.

Article  CAS  PubMed  Google Scholar 

Reilly CR, Shimamura A. Predisposition to myeloid malignancies in Shwachman-diamond syndrome: biological insights and clinical advances. Blood. 2023;141:1513–23.

Article  CAS  PubMed  Google Scholar 

Yu K, et al. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. Blood Adv. 2024;8:497–511.

Article  CAS  PubMed  Google Scholar 

Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119:3815–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aakash F, et al. Contemporary approach to the diagnosis and classification of myelodysplastic neoplasms/syndromes—recommendations from the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Mod Pathol. 2024;37:100615.

Article  CAS  PubMed  Google Scholar 

Akkari YMN, et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022;139:2273–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, et al. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022;36:2306–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haase D, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.

Article  CAS  PubMed  Google Scholar 

Solé F, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90:1168–78.

PubMed  Google Scholar 

Nowell PC, Hungerford DA. Chromosome Studies on Normal and Leukemic Human Leukocytes. J Natl Cancer Inst. 1960;25:85–109.

CAS  PubMed  Google Scholar 

Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87:515–26.

Article  PubMed  PubMed Central  Google Scholar 

Ogawa S. Genetics of MDS. Blood. 2019;133:1049–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.

Article  CAS  PubMed  Google Scholar 

Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia. Nat Rev Cancer. 2017;17:5–19.

Article  CAS  PubMed  Google Scholar 

Homan CC, et al. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023;7:6092–107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

Article  CAS  PubMed  Google Scholar 

Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard E, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1(7).

Nazha A, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39:3737–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maggioni G, et al. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematol. 2023;10:e117–28.

Article  Google Scholar 

Huber S, et al. MDS subclassification—do we still have to count blasts? Leukemia. 2023;37:942–5.

Article  PubMed  PubMed Central  Google Scholar 

Xie Z, et al. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024;144:2033–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weeks LD, et al. Prediction of risk for